+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an additional therapy for adolescents and adults with severe asthma that remains uncontrolled despite treatment with inhaled corticosteroids and other standard asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the efficacy and safety of GB-0895 in improving health outcomes for this population, with an optional open-label extension phase. Participants will receive subcutaneous injections of either GB-0895 or a placebo every six months over a 52-week treatment period. The study includes a screening and run-in phase lasting up to five weeks before treatment starts. After the treatment phase, participants will enter a follow-up period lasting from week 52 to week 90 or may opt to join an open-label extension lasting until week 142. During the study, participants will be regularly assessed for asthma exacerbations, lung function changes, quality of life, symptom control, and safety measures including lab tests, vital signs, and ECGs. Researchers will monitor the annualized asthma exacerbation rate as the primary outcome and evaluate additional respiratory and quality of life assessments. The total participation time may extend up to nearly three years for those in the optional open-label extension.

Age: 12Years - 80YearsAll GendersPhase 3
134 locations